Manuela Olaya

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Rituximab is a chimeric monoclonal antibody against the surface protein CD20 of B cells, used in the treatment of hematologic malignances and autoimmune diseases. Some patients develop hypersensitivity reactions after the infusion. It is unknown the percentage of these which are due to an IgE allergic mechanism. Also, there is not a standardized(More)
  • 1